CD10 expression in primary intestinal large B-cell lymphomas: its clinical significance

Jai Hyang Go1, Woo Ick Yang, Howe J Ree

  • 1Department of Pathology, Dankook University College of Medicine, Cheonan-si, Chungchungnam-do, Korea.

Insights

Over half of primary intestinal large B-cell lymphomas originate from germinal center B cells. CD10 expression in these lymphomas may indicate a better prognosis and treatment response.

Area of Science:

  • Oncology
  • Immunohistochemistry
  • Gastrointestinal Pathology

Background:

  • Primary intestinal large B-cell lymphomas (PILBCL) are a heterogeneous group of tumors.
  • Understanding the cellular origin of PILBCL is crucial for accurate diagnosis and prognosis.

Purpose of the Study:

  • To investigate the prevalence of a germinal center B-cell origin in PILBCL using CD10 expression.
  • To assess the clinical significance and prognostic value of CD10 expression in PILBCL.

Main Methods:

  • Immunohistochemistry was used to detect CD10 and Bcl-6 expression in 32 surgically resected PILBCL tissue samples.
  • CD10 protein expression was correlated with clinical parameters, including disease stage, treatment response, and survival.

Main Results:

  • 47% of PILBCL cases were CD10 positive, often co-expressing Bcl-6.
  • CD10 positive lymphomas were more frequently diagnosed at an earlier stage (Stage I2) and showed a significantly better response to treatment.
  • A trend towards longer overall survival was observed in CD10 positive cases, though not statistically significant.

Conclusions:

  • A significant proportion of PILBCL cases appear to originate from germinal center B cells.
  • CD10 expression is a potential prognostic biomarker for patients with primary intestinal large B-cell lymphomas, indicating a favorable outcome.
Abstract